Advanced

The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension

Sarafidis, PA; Lasaridis, AN; Nilsson, Peter LU ; Hitoglou-Makedou, AD; Pagkalos, EM; Yovos, JG; Pliakos, CI and Tourkantonis, AA (2005) In American Journal of Hypertension 18(2). p.227-234
Abstract
Background: Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension. Methods: The study involved 20 subjects with type 2 DM who were already on 15 mg glibenclamide daily but were achieving poor glycemic control and who had either poorly controlled or newly diagnosed hypertension. In these patients, rosiglitazone (4 mg daily) was added to the existing therapeutic regimen for 26 weeks. At baseline and the end of the... (More)
Background: Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension. Methods: The study involved 20 subjects with type 2 DM who were already on 15 mg glibenclamide daily but were achieving poor glycemic control and who had either poorly controlled or newly diagnosed hypertension. In these patients, rosiglitazone (4 mg daily) was added to the existing therapeutic regimen for 26 weeks. At baseline and the end of the treatment, subjects gave a 24-h urine collection for direct measurement of albumin and a spot specimen for determination of the albumin-to-creatinine ratio (ACR). Subjects also had a hyperinsulinemic euglycemic clamp and an ambulatory blood pressure (BP) monitoring. Results: At the end of the study, UAE was significantly reduced versus baseline, as measured either directly in the 24-h collection (22.4 +/- 4.6 v 13.8 +/- 3.0 mg/day, P <.05) or with ACR (20.9 +/- 3.8 v 14.0 +/- 2.8 mg/g, P < .05). The percentage changes in UAE (DeltaALB for the 24-h collection and AACR for ACR) correlated with the respective changes in IS (r = -0.64, P <.01 for DeltaALB and r -0.48, P =.05 for DeltaACR), systolic BP (r = 0.63,P <.01 and r = 0.58, P <.01 respectively), and diastolic BP (r 0.56, P <.05 and r = 0.50, P <.05 respectively). Conclusions: In this study, treatment of type 2 diabetic hypertensive patients with rosiglitazone significantly decreased UAE. Lowering of BP and improvement of IS should play roles in this UAE reduction. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
urinary albumin excretion, rosiglitazone, electrolytes, mellitus, type 2 diabetes, hypertension
in
American Journal of Hypertension
volume
18
issue
2
pages
227 - 234
publisher
Elsevier
external identifiers
  • wos:000227394100013
  • pmid:15752951
  • scopus:14744285718
ISSN
1941-7225
DOI
10.1016/j.amjhyper.2004.09.010
language
English
LU publication?
yes
id
55409180-c6dc-4391-a91c-6555fb1f8fc0 (old id 251001)
date added to LUP
2007-10-05 14:08:09
date last changed
2017-08-27 04:08:45
@article{55409180-c6dc-4391-a91c-6555fb1f8fc0,
  abstract     = {Background: Thiazolidinediones are antidiabetic agents that improve insulin sensitivity (IS). Accumulating data indicate that these agents provide beneficial effects beyond glycemic control, such as improvement in vascular function. The aim of this study was to determine the effect of rosiglitazone on urine albumin excretion (UAE) in patients with type 2 diabetes mellitus (DM) and hypertension. Methods: The study involved 20 subjects with type 2 DM who were already on 15 mg glibenclamide daily but were achieving poor glycemic control and who had either poorly controlled or newly diagnosed hypertension. In these patients, rosiglitazone (4 mg daily) was added to the existing therapeutic regimen for 26 weeks. At baseline and the end of the treatment, subjects gave a 24-h urine collection for direct measurement of albumin and a spot specimen for determination of the albumin-to-creatinine ratio (ACR). Subjects also had a hyperinsulinemic euglycemic clamp and an ambulatory blood pressure (BP) monitoring. Results: At the end of the study, UAE was significantly reduced versus baseline, as measured either directly in the 24-h collection (22.4 +/- 4.6 v 13.8 +/- 3.0 mg/day, P &lt;.05) or with ACR (20.9 +/- 3.8 v 14.0 +/- 2.8 mg/g, P &lt; .05). The percentage changes in UAE (DeltaALB for the 24-h collection and AACR for ACR) correlated with the respective changes in IS (r = -0.64, P &lt;.01 for DeltaALB and r -0.48, P =.05 for DeltaACR), systolic BP (r = 0.63,P &lt;.01 and r = 0.58, P &lt;.01 respectively), and diastolic BP (r 0.56, P &lt;.05 and r = 0.50, P &lt;.05 respectively). Conclusions: In this study, treatment of type 2 diabetic hypertensive patients with rosiglitazone significantly decreased UAE. Lowering of BP and improvement of IS should play roles in this UAE reduction.},
  author       = {Sarafidis, PA and Lasaridis, AN and Nilsson, Peter and Hitoglou-Makedou, AD and Pagkalos, EM and Yovos, JG and Pliakos, CI and Tourkantonis, AA},
  issn         = {1941-7225},
  keyword      = {urinary albumin excretion,rosiglitazone,electrolytes,mellitus,type 2 diabetes,hypertension},
  language     = {eng},
  number       = {2},
  pages        = {227--234},
  publisher    = {Elsevier},
  series       = {American Journal of Hypertension},
  title        = {The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension},
  url          = {http://dx.doi.org/10.1016/j.amjhyper.2004.09.010},
  volume       = {18},
  year         = {2005},
}